紐約,2022年6月29日葛羅斯律師事務所向下列股東發出以下通知:Spero治療公司。
熱門資訊> 正文
2022-06-30 00:35
NEW YORK, June 29, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spero Therapeutics, Inc..
紐約,2022年6月29日葛羅斯律師事務所向下列股東發出以下通知:Spero治療公司。
Shareholders who purchased shares of SPRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
鼓勵在上市期間購買SPRO股票的股東與公司聯繫,討論可能的主要原告任命事宜。被任命為主要原告不需要參與任何追償。
CONTACT US HERE:
請在此處聯繫我們:
CLASS PERIOD: October 28, 2021 to May 2, 2022
上課時間:2021年10月28日至2022年5月2日
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
指控:起訴書稱,在上課期間,被告發布了重大虛假和/或誤導性陳述和/或未能披露:(I)為支持公司候選產品特比培南HBR的新葯申請(NDA)而提交的數據不足以獲得美國食品和藥物管理局(FDA)的批准;(Ii)因此,FDA不太可能批准目前形式的特比培南HBR NDA;(Iii)上述情況將需要大幅裁員和重組Spero的業務;及(Iv)因此,本公司的公開聲明在所有相關時間均屬重大虛假及誤導性陳述。
DEADLINE: July 25, 2022 Shareholders should not delay in registering for this class action. Register your information here:
截止日期:2022年7月25日股東不應拖延登記參加這起集體訴訟。在此處註冊您的信息:
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPRO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 25, 2022. There is no cost or obligation to you to participate in this case.
股東的下一步行動:一旦您註冊成為在上面列出的時間範圍內購買SPRO股票的股東,您將被登記在投資組合監控軟件中,以在案例的整個生命周期中為您提供狀態更新。尋求成為主要原告的最后期限是2022年7月25日。參與此案對您沒有任何成本或義務。
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
為什麼是格羅斯律師事務所?格羅斯律師事務所是全國公認的集體訴訟律師事務所,我們的使命是保護所有因欺詐、欺詐和非法商業行為而蒙受損失的投資者的權利。格羅斯律師事務所致力於確保公司遵守負責任的商業實踐,並從事良好的企業公民行為。當一家公司的虛假和/或誤導性陳述或重大信息遺漏導致該公司股票人為膨脹時,該公司代表遭受損失的投資者尋求賠償。律師廣告。以前的結果並不能保證類似的結果。
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
聯繫方式:
格羅斯律師事務所
西38街15號,12樓
紐約,紐約州,10018
電子郵件:[受電子郵件保護]
電話:(646)453-8903
SOURCE The Gross Law Firm
來源:葛羅斯律師事務所